Search Results - "Dovedi, S J"

The antitumor immune response generated by fractionated radiation therapy may be limited by tumor cell adaptive resistance and can be circumvented by PD-L1 blockade by Dovedi, S J, Illidge, T M

“…Fractionated radiation therapy (RT) leads to adaptive changes in the tumor microenvironment that may limit the generation of an antitumor immune response. We…”
Get full text

A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells by Cheadle, E J, Lipowska-Bhalla, G, Dovedi, S J, Fagnano, E, Klein, C, Honeychurch, J, Illidge, T M

“…Anti-CD20 monoclonal antibodies (mAb) such as rituximab have been proven to be highly effective at improving outcome in B-cell malignancies. However, many…”
Get full text

Pre-treatment lymphocytopaenia is an adverse prognostic biomarker in muscle-invasive and advanced bladder cancer by Joseph, N., Dovedi, S.J., Thompson, C., Lyons, J., Kennedy, J., Elliott, T., West, C.M., Choudhury, A.

“…Pre-treatment lymphocytopaenia may result from cytokines secreted by the tumour microenvironment in association with aggressive tumour biology. We sought to…”
Get full text

A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells by Cheadle, E J, Lipowska-Bhalla, G, Dovedi, S J, Fagnano, E, Klein, C, Honeychurch, J, Illidge, T M

“…This corrects the article DOI: 10.1038/leu.2016.352…”
Get full text

Cyclooxygenase-2 inhibition: a potential mechanism for increasing the efficacy of bacillus calmette-guerin immunotherapy for bladder cancer by Dovedi, S J, Kirby, J A, Atkins, H, Davies, B R, Kelly, J D

“…Intravesical bacillus Calmette-Guerin (BCG) therapy is the principal treatment for high risk, noninvasive urothelial carcinoma and carcinoma in situ of the…”
Get more information

Sustained tumour eradication after induced caspase-3 activation and synchronous tumour apoptosis requires an intact host immune response by Melis, M H M, Simpson, K L, Dovedi, S J, Welman, A, MacFarlane, M, Dive, C, Honeychurch, J, Illidge, T M

“…Effective anticancer treatments often result in the induction of large amounts of tumour cell death. In vivo , such dying tumour cells are a potential source…”
Get full text

Erratum: A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells by Cheadle, E J, Lipowska-Bhalla, G, Dovedi, S J, Fagnano, E, Klein, C, Honeychurch, J, Illidge, T M

“…Correction to: Leukemia (2017) 31, 1611–1621; doi:10.1038/leu.2016.352; published online 3 January 2017 Following the publication of this article, it was noted…”
Get full text

P03.13 Age-induced changes in anti-tumor immunity alter the tumor immune infiltrate and reduce response to immune-oncology treatments by Sitnikova, S, Morrow, M, Valge-Archer, V, Wilkinson, R W, Robinson, MJ, Dovedi, S J

“…BackgroundImmuno-Oncology research relies heavily on murine syngeneic tumor models. However, whilst the median age for a cancer diagnosis is 65 years or older,…”
Get full text

Rapid functional impairment of natural killer cells following tumor entry limits anti-tumor immunity by Dean, Isaac, Lee, Colin Y. C., Tuong, Zewen K., Li, Zhi, Tibbitt, Christopher A., Willis, Claire, Gaspal, Fabrina, Kennedy, Bethany C., Matei-Rascu, Veronika, Fiancette, Rémi, Nordenvall, Caroline, Lindforss, Ulrik, Baker, Syed Murtuza, Stockmann, Christian, Sexl, Veronika, Hammond, Scott A., Dovedi, Simon J., Mjösberg, Jenny, Hepworth, Matthew R., Carlesso, Gianluca, Clatworthy, Menna R., Withers, David R.

“…Immune cell dysfunction within the tumor microenvironment (TME) undermines the control of cancer progression. Established tumors contain phenotypically…”
Get full text